Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2012-01-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic-hypertensive elderly
Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
Cardiorespiratory performance assessment with ergospirometry test
Biochemical analysis
Hypertensive elderly
Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
Cardiorespiratory performance assessment with ergospirometry test
Biochemical analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiorespiratory performance assessment with ergospirometry test
Biochemical analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of hypertension and/or T2DM for at least 2 years
* member active of the hypertension and diabetes mellitus program
* be on optimized drug therapy for more than 3 months
* BMI above 22 kg/m²;
* no heart disease
* non-insulin-dependent,
* sedentary according to the International Physical Activity Questionnaire (IPAQ) and
* functionally independent.
Exclusion Criteria
* hemodynamic, and electrocardiographic complications;
* respiratory exchange ratio (R) lower than 1.0 at the end of exertion,
* VE/VCO2 value higher than 34 in the first anaerobic threshold;
* chronic atrial fibrillation;
* neuromuscular,
* orthopedic,
* peripheral vascular,
* pulmonary diseases;
* myocardial infarction within 6 months;
* orthopedic limitation or musculoskeletal pain.
60 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal de Pernambuco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniella Cunha Brandao
PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidade Federal de Pernambuco
Recife, Pernambuco, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D'Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006 Jan 3;113(1):20-9. doi: 10.1161/CIRCULATIONAHA.105.567107. Epub 2005 Dec 27.
Hollenberg M, Yang J, Haight TJ, Tager IB. Longitudinal changes in aerobic capacity: implications for concepts of aging. J Gerontol A Biol Sci Med Sci. 2006 Aug;61(8):851-8. doi: 10.1093/gerona/61.8.851.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
etiene
Identifier Type: -
Identifier Source: org_study_id